Drugs / MVA-BN-Brachyury
MVA-BN-Brachyury
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04296942 | May → Oct 2021 | HER2 positive breast carcinoma, triple-negative breast carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04134312 | Jan 2020 → Jan 2021 | metastatic neoplasm | Bavarian Nordic | Completed | No outcome recorded |
| Phase 1 | NCT03349983 | Jan 2018 → Jun 2020 | — | Bavarian Nordic | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03493945 | May 2018 → Oct 2024 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05445882 | Apr 2024 | castration-resistant prostate carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04020094 | Nov 2019 → Apr 2021 | prostate adenocarcinoma | University of Utah | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT03595228 | Oct 2018 → Dec 2021 | chordoma | Bavarian Nordic | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-06-05 | Bavarian Nordic | Results Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma bavarian-nordic.com ↗
As this meets the initial pre-defined threshold of activity for the first stage of the Phase 2 trial, recruitment will be expanded to enroll another 19 patients, while the first 10 patients continue to be treated and evaluated. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-06-05 | Bavarian Nordic | Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma bavarian-nordic.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-BN-Brachyury | “BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury).” NCT05445882 ↗6“Each injection of MVA-BN-Brachyury consists of 2.0 x 10(8) infectious units (Inf.U).” NCT04296942 ↗ “MVA-BN-Brachyury injections will be given on day 0 and 14.” NCT03595228 ↗ |
| Known as | MVA-Bavarian Nordic (BN)-Brachyury | “Recombinant MVA-Bavarian Nordic (BN)-Brachyury recommended phase 2 dose (R2PD)” NCT04296942 ↗ |
| Known as | MVA-BN-brachyury-TRICOM | “Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.” PMID 34479925 ↗ Sep 2021 |
| Modality | Vaccine | “MVA-BN-Brachyury priming and FPV-Brachyury boost vaccines” NCT03349983 ↗ |
| Route | Subcutaneous | “MVA-brachyury s.c., 8 × 108 infectious units (IU)” PMID 31876334 ↗ Dec 2019 |